Glenmark Q4 net profit seen flat at Rs 150cr

Glenmark Pharma will report its fourth quarter results on Tuesday. According to a CNBC-TV18 poll, the pharma major is likely to report a 16 percent year-on-year revenue growth at Rs 1,240 crore.

Its EBITDA seen up by 14 percent to Rs 252 crore and operating profit margin is likely to be around 20.3 percent, slightly lower than 20.8 percent, a year ago.
 
The company's net profit is likely to remain flat at Rs 150 crore, but could surprise as analysts expectations range between Rs 133-167 crore. Topline growth momentum is likely to be sustained with India and US key drivers US business growth will be aided via new launches and low competition products such as Malarone. Glenmark is expected to report 25 percent YoY growth in US sales, while domestic revenue growth is seen around 12 percent. Its revenue from rest of the world/Latin America is likely to increase 20-25 percent, helped by expansion in newer markets and launch of new products.